European Journal of Clinical Pharmacology

, 65:1149

Successful strategy to improve the specificity of electronic statin–drug interaction alerts

  • Hanna Marita Seidling
  • Caroline Henrike Storch
  • Thilo Bertsche
  • Christian Senger
  • Jens Kaltschmidt
  • Ingeborg Walter-Sack
  • Walter Emil Haefeli
Pharmacoepidemiology and Prescription

DOI: 10.1007/s00228-009-0704-x

Cite this article as:
Seidling, H.M., Storch, C.H., Bertsche, T. et al. Eur J Clin Pharmacol (2009) 65: 1149. doi:10.1007/s00228-009-0704-x

Abstract

Purpose

A considerable weakness of current clinical decision support systems managing drug–drug interactions (DDI) is the high incidence of inappropriate alerts. Because DDI-induced, dose-dependent adverse events can be prevented by dosage adjustment, corresponding DDI alerts should only be issued if dosages exceed safe limits. We have designed a logical framework for a DDI alert-system that considers prescribed dosage and retrospectively evaluates the impact on the frequency of statin–drug interaction alerts.

Methods

Upper statin dose limits were extracted from the drug label (SPC) (20 statin-drug combinations) or clinical trials specifying the extent of the pharmacokinetic interaction (43 statin–drug combinations). We retrospectively assessed electronic DDI alerts and compared the number of standard alerts to alerts that took dosage into account.

Results

From among 2457 electronic prescriptions, we identified 73 high-risk statin–drug pairs. Of these, SPC dosage information classified 19 warnings as inappropriate. Data from pharmacokinetic trials took quantitative dosage information more often into consideration and classified 40 warnings as inappropriate. This is a significant reduction in the number of alerts by 55% compared to SPC-based information (26%; p < 0.001).

Conclusion

This retrospective study of pharmacokinetic statin interactions demonstrates that more than half of the DDI alerts that presented in a clinical decision support system were inappropriate if DDI-specific upper dose limits are not considered.

Keywords

Clinical decision support systemsDrug–drug interactionsHMG-CoA-Reductase inhibitorsOver-alertingUpper dose limits

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Hanna Marita Seidling
    • 1
    • 2
  • Caroline Henrike Storch
    • 1
  • Thilo Bertsche
    • 1
    • 2
  • Christian Senger
    • 1
  • Jens Kaltschmidt
    • 1
  • Ingeborg Walter-Sack
    • 1
  • Walter Emil Haefeli
    • 1
    • 2
    • 3
  1. 1.Department of Internal Medicine VI, Clinical Pharmacology and PharmacoepidemiologyUniversity of HeidelbergHeidelbergGermany
  2. 2.Cooperation Unit Clinical PharmacyUniversity of HeidelbergHeidelbergGermany
  3. 3.HeidelbergGermany